Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia
Ralph V. Boccia(Center for Cancer and Blood Disorders), James B. Bussel(Cornell University), Leslie Todd(Tulane University), Quentin A. Hill(Leeds Teaching Hospitals NHS Trust), Waleed Ghanima(Oslo University Hospital), Michael D. Tarantino(Bleeding & Clotting Disorders Institute), Sandra Tong(Rigel (United States)), Michael Boxer(Arizona Oncology), Michelle Sholzberg(St. Michael's Hospital), Nichola Cooper(Imperial College London)
Cited by 71
Related Papers
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
B cell–helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen
|Nature Immunology|2011|724
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
|New England Journal of Medicine|2006|530
COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City
|Modern Pathology|2020|478